We are pleased to announce that the Phase 2 study of picankibart (IBI112), the first domestic IL-23p19 drug candidate for ulcerative colitis in China, has successfully met the primary endpoint. This trial marks a significant milestone in evaluating the efficacy and safety of picankibart, offering hope for more innovative treatment options for patients living with moderate-to-severe ulcerative colitis.� https://lnkd.in/gWsbeWTr #InnoventBiologics #Autoimmune
Innovent Biologics
Pharmaceutical Manufacturing
Suzhou, Jiangsu 24,257 followers
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people
About us
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT� (sintilimab injection), BYVASDA� (bevacizumab injection), SULINNO� (adalimumab injection), HALPRYZA� (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT� was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.
- Website
-
http://www.innoventbio.com
External link for Innovent Biologics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Suzhou, Jiangsu
- Type
- Public Company
- Founded
- 2011
- Specialties
- Biologics Manufacturing, Monoclonal Antibodies, Biosimilars, and Novel Drugs
Locations
Employees at Innovent Biologics
Updates
-
Innovent is pleased to announce a strategic collaboration with 江苏奥赛康药业股份有限公司 ASK Pharm for limertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) for lung cancer treatment. Limertinib, an orally administered novel therapy currently under review by China’s NMPA, offers a promising new option for patients with advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). #InnoventBiologics #Oncology https://lnkd.in/gMhkMmPX
-
The New Drug Application for picankibart injection, a recombinant anti-IL-23p19 antibody, has been accepted by the Center for Drug Evaluation of China's NMPA for the treatment of moderate to severe plaque psoriasis. As the first IL-23p19 antibody to demonstrate over 80% of subjects achieving PASI 90 at 16 weeks, picankibart also offers the longest maintenance dosing interval in its class, delivering significant clinical benefits and improving quality of life for patients. https://lnkd.in/gCjgDQ9N #InnoventBiologics #psoriasis
-
Congratulations to the recipients of the 2024 #LaskerAward for their groundbreaking work in GLP-1-based drugs, transforming obesity treatment worldwide. Their discoveries laid the foundation for a new generation of therapies, including the GLP-1R/GCGR dual agonist Mazdutide, which builds on the successes of earlier treatments, expanding the potential for even greater weight loss and metabolic health improvements. Learn more about the remarkable history and future of GLP-1-based therapies below. The Albert and Mary Lasker Foundation #InnoventBiologics #Mazdutide #glp1 https://lnkd.in/eG3SyZAN https://lnkd.in/g4_8cpmc
-
At #ESMO24, we also had the valuable opportunity to present clinical data for IBI354, a HER2 monoclonal antibody-camptothecin derivative conjugate. With extremely low exposure of free toxin in circulation and an ideal safety profile from pre-clinical and clinical studies, IBI354 shows great promise for patients with advanced tumor types, including breast cancer, ovarian cancer and colorectal cancer. https://lnkd.in/g2D2Qwgk
-
Exciting new clinical data on IBI363, Innovent's first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in combination with bevacizumab for advanced colorectal cancer has been shared at the 2024 ESMO - European Society for Medical Oncology . With ongoing studies investigating IBI363 in other cancers such as NSCLC, melanoma, and additional solid tumors, we remain hopeful about its potential to bring new treatment options to even more patients. https://lnkd.in/gJHjwqAd #ESMO24 #InnoventBiologics #OncologyCommunity
-
Our Phase 3 DREAMS-2 trial results for mazdutide, a GLP-1R and GCGR dual agonist, were presented as a late-breaking session at #EASD2024. Mazdutide showed superior glycemic control and weight reduction compared to dulaglutide in Chinese adults with type 2 diabetes, along with improvements in key cardiometabolic risk factors. Access the EASD presentation results below. https://lnkd.in/gZheqzBQ�
-
We're excited to share encouraging Phase 1 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2024 World Conference on Lung Cancer. The data shows efficacy in advanced NSCLC, offering new treatment possibilities for patients with limited options. With ongoing Phase 1/2 trials, we remain committed to advancing innovative therapies for those in need. https://lnkd.in/gY2aWHKj #InnoventBiologics #wclc24
-
Innovent Biologics, in partnership with Stars Youth Development Center, has successfully completed its third annual Children's Book Donation event, distributing nearly 2,000 books to three rural primary schools in Shanxi, Gansu, and Inner Mongolia, and benefiting nearly 2,000 students and teachers. This initiative seeks to close the educational resource gap in remote areas by providing carefully selected literature to inspire creativity and broaden horizons for children. This book donation is part of Innovent's broader commitment to community well-being, which also includes running free clinics, organizing employee blood drives, holding appreciation events for caregivers, and managing extensive patient assistance programs. With drug donations worth over RMB 3.4 billion reaching more than 170,000 patients, these initiatives, fueled by the dedication of our teams, truly bring our mission to life: developing high-quality, affordable biopharmaceuticals while making a meaningful difference in the communities we serve.
-
We're excited to connect with the oncology community at the 2024 World Conference on Lung Cancer in San Diego, where our team will present updated results from the pivotal Phase 2 trial of Dupert� (fulzerasib) for advanced NSCLC with the KRAS G12C mutation. As a potent KRAS G12C inhibitor, Dupert� represents an innovative treatment option for patients who have received prior systemic therapy, recently earning NMPA approval. https://lnkd.in/g6FbhrX9 #InnoventBiologics #wclc24